Form 4: Korro Bio General Counsel Granted 41,902 RSUs

Korro Bio's General Counsel, Jeffrey Cerio, was granted 41,902 restricted stock units (RSUs) that will vest in two tranches in 2026.

Summary

• Jeffrey Cerio, General Counsel of Korro Bio, Inc. (KRRO), was granted 41,902 shares of common stock in the form of restricted stock units (RSUs).
• The transaction date for this grant was December 15, 2025.
• The RSUs were granted at a price of $0.00 per share.
• These RSUs will vest in two equal tranches: 50% on June 15, 2026, and the remaining 50% on December 15, 2026.
• Vesting is contingent upon Mr. Cerio maintaining a continuous Service Relationship with Korro Bio, Inc. through each vesting date, as defined in the company's 2023 Stock Option and Incentive Plan.

Sentiment

Score: 6

Explanation: The RSU grant is a routine compensation event, slightly positive as it indicates executive retention and alignment of interests, but not a significant market-moving event.

Positives

• The RSU grant aligns the General Counsel's long-term interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This grant serves as a retention mechanism, incentivizing the General Counsel to remain with the company through the vesting periods.

Negatives

• The future vesting of these RSUs will result in a minor dilution of existing shareholder equity, which is a common aspect of equity-based compensation plans.

Risks

• The vesting of the restricted stock units is subject to the reporting person maintaining a continuous Service Relationship with Korro Bio, Inc. through the specified vesting dates.

Future Outlook

The grant of restricted stock units with future vesting dates indicates an expectation of continued service from the General Counsel and aligns his future financial incentives with the company's long-term performance.

Industry Context

The grant of restricted stock units to key executives is a standard practice in the biotechnology and broader corporate sectors. It is a common form of long-term incentive compensation designed to attract, retain, and motivate talent by linking their financial success to the company's stock performance.

Comparison to Industry Standards

• The RSU grant to Korro Bio's General Counsel is consistent with typical executive compensation practices across the biotechnology industry, where equity-based incentives are a significant component of total compensation.
• The vesting schedule, split over two future dates, is a common structure used to ensure executive retention and long-term commitment, similar to grants observed at comparable early-stage biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience minor future dilution upon vesting, but benefit from increased alignment of executive interests with long-term company performance.
• Employees (General Counsel): Receives significant long-term incentive compensation, enhancing retention and motivation.

Next Steps

• The first tranche of 50% of the RSUs is scheduled to vest on June 15, 2026.
• The second tranche of 50% of the RSUs is scheduled to vest on December 15, 2026.

Key Dates

Recommendation

This Form 4 reports a routine RSU grant to an executive, which is a standard component of compensation and does not present new material information that would alter an investment thesis or warrant a change in stock recommendation. It primarily reflects ongoing executive retention and alignment.

Keywords

Korro Bio, KRRO, Jeffrey Cerio, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Equity Grant, Form 4